Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension

Journal of Rheumatology

Volumn 37, Issue 12, 2010, Pages 2531-2539

  Rosato, Edoardo ^a   Molinaro, Ilenia ^a   Borghese, Federica ^a   Rossi, Carmelina ^a   Pisarri, Simonetta ^a   Salsano, Felice ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bosentan; Laser Doppler perfusion imaging; Raynaud's phenomenon; Skin blood flow; Systemic sclerosis

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT;

ADULT; ARTICLE; BLOOD RHEOLOGY; CAPILLAROSCOPY; CONTROLLED STUDY; FEMALE; HAND; HUMAN; IMAGING SYSTEM; LASER DOPPLER FLOWMETRY; LASER DOPPLER PERFUSION IMAGING; MAJOR CLINICAL STUDY; MALE; METACARPOPHALANGEAL JOINT; NAILFOLD VIDEOCAPILLAROSCOPY; PRIORITY JOURNAL; PROXIMAL INTERPHALANGEAL JOINT; PULMONARY HYPERTENSION; RAYNAUD CONDITION SCORE; RAYNAUD PHENOMENON; SCORING SYSTEM; SKIN BLOOD FLOW; SURFACE PROPERTY; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LASER-DOPPLER FLOWMETRY; MALE; MIDDLE AGED; RAYNAUD DISEASE; REGIONAL BLOOD FLOW; SCLERODERMA, SYSTEMIC; SKIN; SULFONAMIDES;

EID: 78649723957     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100358     Document Type: Article

References (30)

1. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1998;15:202-5.
2. Kahaleh MB. Vascular involvement in systemic sclerosis (SSc). Clin Exp Rheumatol 2004;22 Suppl 33:19-23.
3. Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology 2005;44:587-96.
4. Flavahan NA, Flavahan S, Mitra S, Chotani MA. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 2003;29:275-91.
5. Salsano F, Letizia C, Proietti M, Rossi C, Proietti AR, Rosato E, et al. Significant changes of peripheral perfusion and plasma adrenomedullin levels in acetylcysteine long term treatment of patients with sclerodermic Raynaud's phenomenon. Int J Immunopathol Pharmacol 2005;18:761-70.
6. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:1336-40.
7. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
8. Murray AK, Moore TL, Manning JB, Taylor C, Griffiths CE, Herrick AL. Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. Arthritis Rheum 2009;61:1103-11.
9. Rosato E, Borghese F, Pisarri S, Salsano F. Laser Doppler perfusion imaging is useful in the study of Raynaud's phenomenon and improves the capillaroscopic diagnosis. J Rheumatol 2009;36:2257-63.
10. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
11. Rubin LJ; American College of Chest Physicians. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126 Suppl 1:7-10.
12. Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clin Exp Rheumatol 2003;21 Suppl 29:39-41.
13. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of severity and prognosis. Clin Exp Rheumatol 2003;21 Suppl 29:42-6.
14. Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000;27:155-60.
15. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46:2410-20.
16. Yamane K. Endothelin and collagen vascular disease: a review with special reference to Raynaud's phenomenon and systemic sclerosis. Intern Med 1994;33:579-82.
17. Herrick AL. Vascular function in systemic sclerosis. Curr Opin Rheumatol 2000;12:527-33.
18. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, et al. Circulating endothelin-1 levels in systemic sclerosis subsets - a marker of fibrosis or vascular dysfunction? J Rheumatol 1994;21:1838-44.
19. Mugii N, Hasegawa M, Hamaguchi Y, Tanaka C, Kaji K, Komura K, et al. Reduced red blood cell velocity in nail-fold capillaries as a sensitive and specific indicator of microcirculation injury in systemic sclerosis. Rheumatology 2009;48:696-703.
20. Cutolo M, Ferrone C, Pizzorni C, Soldano S, Seriolo B, Sulli A. Peripheral blood perfusion correlates with microvascular abnormalities in systemic sclerosis: A laser-Doppler and nailfold videocapillaroscopy study. J Rheumatol 2010;37:1174-80.
21. Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 2007;56:1985-93.
22. Cardillo C, Schinzari F, Melina D, Mores N, Bosello S, Peluso G, et al. Improved endothelial function after endothelin receptor blockade in patients with systemic sclerosis. Arthritis Rheum 2009;60:1840-4.
23. Selenko-Gebauer N, Duschek N, Minimair G, Stingl G, Karlhofer F. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan. Rheumatology 2006;45 Suppl:45-8.
24. Dunne J, Dutz J, Shojania K, Ng B, Van Eeden S. Treatment of severe Raynaud's phenomenon with bosentan in a patient with systemic sclerosis. Rheumatology 2006;45:911-2.
25. Hettema ME, Zhang D, Stienstra Y, Smit AJ, Bootsma H, Kallenberg CG. No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis. Clin Rheumatol 2009;28:825-33.
26. Grunfeld S, Hamilton CA, Mesaros S, McClain SW, Dominiczak AF, Bohr DF, et al. Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension 1995;26:854-7.
27. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998;97:2222-9.
28. Shi-wen X, Kennedy L, Renzoni EA, Bou-Gharios G, du Bois RM, Black CM, et al. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor β in human lung fibroblasts. Arthritis Rheum 2007;56:4189-94.
29. Nguyen VA, Eisendle K, Gruber I, Hugl B, Reider D, Reider N, et al. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology 2010;49:583-7.
30. Hettema ME, Zhang D, Bootsma H, Kallenberg CGM. Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 2007;66:1398-9.